Literature DB >> 34594709

Global Trends and Regional Differences in Hepatitis C Virus Infection Prevalence and Implications for Prevention - Worldwide, 1990-2017.

Wenzhan Jing1, Jue Liu1, Min Liu1.   

Abstract

WHAT IS ALREADY KNOWN ON THIS TOPIC?: The global prevalence of hepatitis C virus (HCV) infection in 2015 has been modeled to assess the disease burden in 21 Global Burden of Disease (GBD) regions. However, there is no study to clarify the global long-term trends and regional differences in HCV infection prevalence. WHAT IS ADDED BY THIS REPORT?: This report clarified the global temporal trends and regional differences in HCV infection prevalence. Global HCV infection age-standardized prevalence rate (ASR) gradually decreased from 1990 to 2017 except in Eastern Europe, and liver cancer due to hepatitis C ASR increased worldwide with drastic shifts in low-middle Socio-Demographic Index (SDI) regions in the last decade. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: HCV is still prevalent worldwide despite the development of highly effective direct-acting antivirals (DAAs) and showed a reemergence concurrent with the opioid crisis. HCV infection prevention might involve at least 3 aspects: first, prohibiting HCV widespread transmission among general populations; second, increasing global DAAs coverage; and third, continuously investing in the development of the HCV vaccine. Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2020.

Entities:  

Year:  2020        PMID: 34594709      PMCID: PMC8422239          DOI: 10.46234/ccdcw2020.151

Source DB:  PubMed          Journal:  China CDC Wkly        ISSN: 2096-7071


  6 in total

1.  Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

Authors:  Fabrice Carrat; Hélène Fontaine; Céline Dorival; Mélanie Simony; Alpha Diallo; Christophe Hezode; Victor De Ledinghen; Dominique Larrey; Georges Haour; Jean-Pierre Bronowicki; Fabien Zoulim; Tarik Asselah; Patrick Marcellin; Dominique Thabut; Vincent Leroy; Albert Tran; François Habersetzer; Didier Samuel; Dominique Guyader; Olivier Chazouilleres; Philippe Mathurin; Sophie Metivier; Laurent Alric; Ghassan Riachi; Jérôme Gournay; Armand Abergel; Paul Cales; Nathalie Ganne; Véronique Loustaud-Ratti; Louis D'Alteroche; Xavier Causse; Claire Geist; Anne Minello; Isabelle Rosa; Moana Gelu-Simeon; Isabelle Portal; François Raffi; Marc Bourliere; Stanislas Pol
Journal:  Lancet       Date:  2019-02-11       Impact factor: 79.321

Review 2.  Hepatitis C.

Authors:  C Wendy Spearman; Geoffrey M Dusheiko; Margaret Hellard; Mark Sonderup
Journal:  Lancet       Date:  2019-10-19       Impact factor: 79.321

Review 3.  Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review.

Authors:  Harleen K Dyal; Maria Aguilar; Taft Bhuket; Benny Liu; Edward W Holt; Sharon Torres; Ramsey Cheung; Robert J Wong
Journal:  Dig Dis Sci       Date:  2015-07-03       Impact factor: 3.199

4.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-08       Impact factor: 79.321

5.  Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018.

Authors:  A Blythe Ryerson; Sarah Schillie; Laurie K Barker; Benjamin A Kupronis; Carolyn Wester
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-10       Impact factor: 17.586

6.  Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.

Authors:  Alastair Heffernan; Graham S Cooke; Shevanthi Nayagam; Mark Thursz; Timothy B Hallett
Journal:  Lancet       Date:  2019-01-29       Impact factor: 202.731

  6 in total
  2 in total

1.  Burden and Trends of Acute Viral Hepatitis in Asia from 1990 to 2019.

Authors:  Qiao Liu; Min Liu; Jue Liu
Journal:  Viruses       Date:  2022-05-28       Impact factor: 5.818

2.  Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis.

Authors:  Jing Xie; Bin Xu; Linlin Wei; Chunyang Huang; Wei Liu
Journal:  Infect Dis Ther       Date:  2022-06-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.